HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Neonates with severe infantile hepatic hemangioendothelioma: limitations of liver transplantation.

Abstract
IHHE as the most common vascular tumor of the liver in infancy can present with acute postnatal liver and congestive heart failure. LTx may be a lifesaving option, but can be complicated by extrahepatic involvement and bleeding complications, especially in neonates. Here we discuss the benefit of LTx in cases of acute postnatal deterioration and massive extent of the hepatic tumor. Three infants with IHHE were transplanted at our institution between 2005 and 2007. Two were neonates with acute postnatal decompensation and progressive liver and heart failure within days. Treatment with steroids and chemotherapy was ineffective; resection surgery and interventional treatment were not considered appropriate. LTx was performed at the age of 7 and 24 days, respectively. An additional infant with a bilobar tumor that evolved more slowly was transplanted on day-of-life 56. Patients 1 and 2 had to be resuscitated during the LTx procedure because of massive bleeding and both died during the procedure. Patient 3 had a complicated post-operative course but is doing well one-yr post-LTx. Neonates with extended hepatic and extrahepatic involvement of IHHE should be evaluated carefully prior to LTx. Whenever possible, alternative interventional treatment options should be considered.
AuthorsEnke Grabhorn, Andrea Richter, Lutz Fischer, Dorothee Krebs-Schmitt, Rainer Ganschow
JournalPediatric transplantation (Pediatr Transplant) Vol. 13 Issue 5 Pg. 560-4 (Aug 2009) ISSN: 1399-3046 [Electronic] Denmark
PMID18992050 (Publication Type: Case Reports, Journal Article)
Chemical References
  • Antineoplastic Agents
  • Steroids
Topics
  • Antineoplastic Agents (pharmacology)
  • Female
  • Hemangioendothelioma (therapy)
  • Humans
  • Infant, Newborn
  • Liver Neoplasms (therapy)
  • Liver Transplantation (methods)
  • Male
  • Steroids (therapeutic use)
  • Time Factors
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: